{
  "question_stem": {
    "en": "An 8-year-old boy is brought to the hospital due to severe headache and altered mental status. An aggressive, high-risk neuroblastoma is diagnosed. As part of his treatment, the patient will receive an autologous bone marrow transplant using stem cells obtained from his peripheral blood. His pretransplant evaluation reveals a history of Epstein-Barr virus infection. This patient is at greatest risk for which of the following after transplantation?",
    "zh": "一名8岁男孩因严重头痛和精神状态改变被送往医院。诊断为侵袭性、高危神经母细胞瘤。作为治疗的一部分，患者将接受自体骨髓移植，使用从其外周血中获得的干细胞。他的移植前评估显示有EB病毒感染史。该患者在移植后最有可能面临以下哪种风险？"
  },
  "question": {
    "en": "This patient is at greatest risk for which of the following after transplantation?",
    "zh": "该患者在移植后最有可能面临以下哪种风险？"
  },
  "options": {
    "A": {
      "en": "Acute transplant rejection",
      "zh": "急性移植排斥"
    },
    "B": {
      "en": "Chronic transplant rejection",
      "zh": "慢性移植排斥"
    },
    "C": {
      "en": "Graft versus host disease",
      "zh": "移植物抗宿主病"
    },
    "D": {
      "en": "New primary Epstein-Barr virus infection",
      "zh": "新的原发性EB病毒感染"
    },
    "E": {
      "en": "Reactivation of Epstein-Barr virus",
      "zh": "EB病毒再激活"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "Patients who undergo hematopoietic stem cell transplantation (HCT) first receive myeloablative chemotherapy, a regimen of highly cytotoxic medications that irreversibly kill existing hematopoietic stem cells. Once pancytopenia is established, patients then receive an infusion of donor hematopoietic stem cells, which engraft in the bone marrow, proliferate, and subsequently reconstitute peripheral blood cells. Donor cells are classified as allogeneic when they are obtained from a related or an unrelated donor and autologous when they are obtained from the patient (eg, preprocedure peripheral blood or umbilical cord blood banked at birth).\n\nWith autologous transplantation, the human leukocyte antigens on major histocompatibility complex class I and II molecules will be a perfect match because the donor and recipient are the same individual. Therefore, there is no risk of graft rejection (host cells attack the graft) or graft versus host disease (graft cells attack the host) because the delineation between self and nonself is preserved (Choices A, B, and C).\n\nAlthough patients who undergo autologous HCT do not require ongoing immunosuppressive medications following HCT (due to the perfect match between donor and recipient), exposure to myeloablative chemotherapy causes a period of temporary, profound immunosuppression until donor cells engraft and reconstitute the peripheral blood cells. During this period of immunosuppression, chronic or latent infections may worsen. Risk is particularly high for the reactivation of human herpesviruses (eg, EPSTEIN-BARR virus, cytomegalovirus, varicella-zoster virus, herpes simplex virus), which establish life-long latent infections and require an intact cytotoxic T-cell response for control.\n\n(Choice D) There is little risk of transfusing a new bloodborne infection (eg, primary EBV, hepatitis virus, cytomegalovirus) in autologous HCT because the donor cells are obtained from the patient themself.\n\nEducational objective:\nAutologous hematopoietic stem cell transplantation reinfuses host cells from the patient’s peripheral blood or banked cord blood to reconstitute the bone marrow. Because the reinfused cells are genetically identical to the host’s, there is no risk of graft rejection or graft versus host disease. Although there is also no risk of transferring a new bloodborne pathogen, chronic or latent infections (eg, Epstein-Barr virus, cytomegalovirus, varicella-zoster virus) may worsen due to the transient immunosuppression induced by myeloablative chemotherapy.",
    "zh": "接受造血干细胞移植 (HCT) 的患者首先接受清髓化疗，这是一种高细胞毒性药物的治疗方案，可不可逆地杀死现有的造血干细胞。一旦发生全血细胞减少，患者随后会接受供者造血干细胞的输注，这些细胞在骨髓中植入、增殖，随后重建外周血细胞。当供者细胞来自相关或无关供者时，将其分类为同种异体，当供者细胞来自患者自身时（例如，术前外周血或出生时储存的脐带血），将其分类为自体。\n\n对于自体移植，由于供者和受者是同一个人，主要组织相容性复合物 I 类和 II 类分子的白细胞抗原将完全匹配。因此，不存在移植物排斥（宿主细胞攻击移植物）或移植物抗宿主病（移植物细胞攻击宿主）的风险，因为自身和非自身的界限得以保留（选项 A、B 和 C）。\n\n尽管接受自体 HCT 的患者在 HCT 后不需要持续的免疫抑制药物治疗（由于供者和受者之间的完美匹配），但暴露于清髓化疗会导致一段短暂的、严重的免疫抑制，直到供者细胞植入并重建外周血细胞。在免疫抑制期间，慢性或潜伏性感染可能会恶化。人疱疹病毒（例如，EB病毒、巨细胞病毒、水痘-带状疱疹病毒、单纯疱疹病毒）再激活的风险特别高，这些病毒会建立终生潜伏感染，并需要完整的细胞毒性 T 细胞反应来控制。\n\n（选项 D）自体 HCT 中输注新的血源性感染（例如，原发性 EBV、肝炎病毒、巨细胞病毒）的风险很小，因为供者细胞来自患者自身。\n\n教育目标：\n自体造血干细胞移植重新输入来自患者外周血或储存的脐带血的宿主细胞，以重建骨髓。由于重新输入的细胞与宿主的基因完全相同，因此不存在移植物排斥或移植物抗宿主病的风险。虽然也不存在转移新的血源性病原体的风险，但由于清髓化疗引起的短暂免疫抑制，慢性或潜伏性感染（例如，EB病毒、巨细胞病毒、水痘-带状疱疹病毒）可能会恶化。"
  },
  "summary": {
    "en": "This question tests the complications associated with autologous bone marrow transplantation, specifically the risk of viral reactivation due to transient immunosuppression. It requires understanding the difference between autologous and allogeneic transplants and their respective risks.\n\nTo solve this question, recognize that autologous transplants do not carry the risk of graft rejection or graft-versus-host disease. The key is to identify the transient immunosuppression following myeloablative chemotherapy as the primary risk factor for reactivation of latent viral infections.",
    "zh": "本题考察与自体骨髓移植相关的并发症，特别是由于短暂性免疫抑制引起的病毒再激活的风险。它需要理解自体移植和异体移植的区别及其各自的风险。\n\n要解决这个问题，需要认识到自体移植不携带移植物排斥或移植物抗宿主病的风险。关键是要确定清髓化疗后的短暂免疫抑制是潜伏病毒感染再激活的主要危险因素。"
  },
  "tags": "Autologous bone marrow transplant; Hematopoietic stem cell transplantation; Epstein-Barr virus; Viral reactivation; Immunosuppression; Neuroblastoma; Oncology",
  "category": "Blood",
  "question_id": "2077",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Blood 23\\2077",
  "extracted_at": "2025-11-05T11:32:13.204148",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:31:14.365890",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}